Iran produces tissue plasminogen activator (tPA)


Researchers at the knowledge-based company Zist Darou have produced tissue plasminogen activator (tPA).
Iran produces tPA
Houshmand Ilka, managing director of the company, said the medication is used for the immediate treatment of myocardial infarction (MI), according to Saturday’s edition of ‘Iran Daily’.

He added that the company intends to supply the product to regional and trans-regional markets.

Myocardial infarction or acute myocardial infarction is the medical term for an event commonly known as a heart attack. An MI occurs when blood stops flowing properly to a part of the heart and the heart muscle is injured because it is not receiving enough oxygen.

Usually this is because one of the coronary arteries that supplies blood to the heart develops a blockage due to an unstable buildup of white blood cells, cholesterol and fat.

Back to top button